Movement Alert｜BEONE MEDICINES Rises 3.05% in Regular Trading, Q2 Global Revenue Hits $1.7 Billion with 30% YoY Growth

Market Focus

Yesterday

On August 26, BEONE MEDICINES rose 3.05% in regular trading, trading at 231.0 HKD/share, with turnover of HKD 109 million.

On the news front, the company's audit committee reviewed and released interim results for the six months ended June 30. Second-quarter global revenue reached USD 1.7 billion, up 30% year-over-year, with core product Brukinsa generating USD 1.2 billion in global revenue, up 31% year-over-year. For the first half, total operating revenue was RMB 22.22 billion, up 26.8% YoY, while net profit attributable to shareholders surged 627.1% to RMB 3.27 billion, driven by accelerating global commercialization.

Meanwhile, the broader biotech sector rallied strongly, with CanSinoBio up 18.64%, Innovent Bio up 11.89%, Everest Medicines up 8.03%, and Akeso up 7.82%, providing additional sector tailwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au.tigermarketb.com/news/1181439300"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181439300\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181439300?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-26 09:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181439300","market":"us","top_or_hot":-1,"title":"Movement Alert｜BEONE MEDICINES Rises 3.05% in Regular Trading, Q2 Global Revenue Hits $1.7 Billion with 30% YoY Growth","media":"Market Focus","content":"<p><p>On August 26, BEONE MEDICINES rose 3.05% in regular trading, trading at 231.0 HKD/share, with turnover of HKD 109 million.</p><p>On the news front, the company's audit committee reviewed and released interim results for the six months ended June 30. Second-quarter global revenue reached USD 1.7 billion, up 30% year-over-year, with core product Brukinsa generating USD 1.2 billion in global revenue, up 31% year-over-year. For the first half, total operating revenue was RMB 22.22 billion, up 26.8% YoY, while net profit attributable to shareholders surged 627.1% to RMB 3.27 billion, driven by accelerating global commercialization.</p><p>Meanwhile, the broader biotech sector rallied strongly, with CanSinoBio up 18.64%, Innovent Bio up 11.89%, Everest Medicines up 8.03%, and Akeso up 7.82%, providing additional sector tailwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BEONE MEDICINES Rises 3.05% in Regular Trading, Q2 Global Revenue Hits $1.7 Billion with 30% YoY Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BEONE MEDICINES Rises 3.05% in Regular Trading, Q2 Global Revenue Hits $1.7 Billion with 30% YoY Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-26 09:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 26, BEONE MEDICINES rose 3.05% in regular trading, trading at 231.0 HKD/share, with turnover of HKD 109 million.</p><p>On the news front, the company's audit committee reviewed and released interim results for the six months ended June 30. Second-quarter global revenue reached USD 1.7 billion, up 30% year-over-year, with core product Brukinsa generating USD 1.2 billion in global revenue, up 31% year-over-year. For the first half, total operating revenue was RMB 22.22 billion, up 26.8% YoY, while net profit attributable to shareholders surged 627.1% to RMB 3.27 billion, driven by accelerating global commercialization.</p><p>Meanwhile, the broader biotech sector rallied strongly, with CanSinoBio up 18.64%, Innovent Bio up 11.89%, Everest Medicines up 8.03%, and Akeso up 7.82%, providing additional sector tailwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1181439300","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181439300","pubTimestamp":1787708434,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 26, BEONE MEDICINES rose 3.05% in regular trading, trading at 231.0 HKD/share, with turnover of HKD 109 million.On the news front, the company's audit committee reviewed and released...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"动向提醒|BEONE MEDICINES常规交易上涨3.05%，Q2全球收入达17亿美元，同比增长30%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"On August 26, BEONE MEDICINES rose 3.05% in regular trading, trading at 231.0 HKD/share, with turnover of HKD 109 million.On the news front, the company's audit committee reviewed and released interim results for the six months ended June 30. Second-quarter global revenue reached USD 1.7 billion, up 30% year-over-year, with core product Brukinsa generating USD 1.2 billion in global revenue, up 31% year-over-year. For the first half, total operating revenue was RMB 22.22 billion, up 26.8% YoY, while net profit attributable to shareholders surged 627.1% to RMB 3.27 billion, driven by accelerating global commercialization.Meanwhile, the broader biotech sector rallied strongly, with CanSinoBio up 18.64%, Innovent Bio up 11.89%, Everest Medicines up 8.03%, and Akeso up 7.82%, providing additional sector tailwinds.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}